IRLAB Therapeutics AB (publ) (IRLAB-A) - Total Liabilities

Latest as of December 2025: Skr107.49 Million SEK ≈ $11.57 Million USD

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has total liabilities worth Skr107.49 Million SEK (≈ $11.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

IRLAB Therapeutics AB (publ) - Total Liabilities Trend (2013–2025)

This chart illustrates how IRLAB Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See IRLAB Therapeutics AB (publ) (IRLAB-A) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

IRLAB Therapeutics AB (publ) Competitors by Total Liabilities

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Magnum Mining and Exploration Ltd AU:MGU	Australia	AU$1.11 Million
Magna Terra Minerals Inc V:MTT	Canada	CA$710.98K
Baillie Gifford US Growth Trust PLC LSE:USA	UK	GBX39.47 Million
Euro Manganese Inc V:EMN	Canada	CA$34.22 Million
Serica Energy PLC LSE:SQZ	UK	GBX1.50 Billion
Alligator Bioscience AB ST:ATORX	Sweden	Skr103.74 Million
Indonesian Tobacco Tbk PT JK:ITIC	Indonesia	Rp184.04 Billion
Advanced Packaging Tech (Malaysia) KLSE:9148	Malaysia	RM25.58 Million

Liability Composition Analysis (2013–2025)

This chart breaks down IRLAB Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IRLAB Therapeutics AB (publ) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	0.76	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.78	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how IRLAB Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for IRLAB Therapeutics AB (publ) (2013–2025)

The table below shows the annual total liabilities of IRLAB Therapeutics AB (publ) from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr107.49 Million ≈ $11.57 Million	+3.78%
2024-12-31	Skr103.58 Million ≈ $11.15 Million	+68.81%
2023-12-31	Skr61.36 Million ≈ $6.60 Million	+87.50%
2022-12-31	Skr32.72 Million ≈ $3.52 Million	-55.15%
2021-12-31	Skr72.97 Million ≈ $7.85 Million	+228.86%
2020-12-31	Skr22.19 Million ≈ $2.39 Million	-15.44%
2019-12-31	Skr26.24 Million ≈ $2.82 Million	+110.59%
2018-12-31	Skr12.46 Million ≈ $1.34 Million	+56.32%
2017-12-31	Skr7.97 Million ≈ $857.81K	-13.57%
2016-12-31	Skr9.22 Million ≈ $992.54K	+1.74%
2015-12-31	Skr9.06 Million ≈ $975.54K	-49.23%
2014-12-31	Skr17.86 Million ≈ $1.92 Million	+254971.43%
2013-12-31	Skr7.00K ≈ $753.31	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$11.36 Million

Skr105.56 Million SEK

Market Cap Rank

#26738 Global

#581 in Sweden

Share Price

Skr1.24

Change (1 day)

+0.81%

52-Week Range

Skr1.20 - Skr6.61

All Time High

Skr104.95